Mitochondrial dysfunction and oxidative stress in Parkinson's disease

Progress in Neurobiology

Volumn 106-107, Issue , 2013, Pages 17-32

  Subramaniam, Sudhakar Raja ^a   Chesselet, Marie Francoise ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Mitochondrial dysfunction; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; CALCIUM; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; MANEB; MITOCHONDRIAL DNA; PARAQUAT; PARKIN; PINK1 PROTEIN; PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ROTENONE; UNCLASSIFIED DRUG;

CALCIUM HOMEOSTASIS; COMPLEX I DEFICIENCY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENE MUTATION; HUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

MITOCHONDRIAL DYSFUNCTION; PARKINSON'S DISEASE;

ANIMALS; APOPTOSIS; DOPAMINERGIC NEURONS; HUMANS; MITOCHONDRIA; MUTATION; OXIDATIVE STRESS; PARKINSON DISEASE;

EID: 84881027032     PISSN: 03010082     EISSN: 18735118     Source Type: Journal    
DOI: 10.1016/j.pneurobio.2013.04.004     Document Type: Review

References (263)

1. Abbas N., Lucking C.B., Ricard S., Durr A., Bonifati V., De Michele G., Bouley S., Vaughan J.R., Gasser T., Marconi R., Broussolle E., Brefel-Courbon C., Harhangi B.S., Oostra B.A., Fabrizio E., Bohme G.A., Pradier L., Wood N.W., Filla A., Meco G., Denefle P., Agid Y., Brice A. A wide variety of mutations in the parkin gene are responsible for autosomal recessive parkinsonism in Europe. French Parkinson's Disease Genetics Study Group and the European Consortium on Genetic Susceptibility in Parkinson's Disease. Human Molecular Genetics 1999, 8:567-574.
2. Amo T., Sato S., Saiki S., Wolf A.M., Toyomizu M., Gautier C.A., Shen J., Ohta S., Hattori N. Mitochondrial membrane potential decrease caused by loss of PINK1 is not due to proton leak, but to respiratory chain defects. Neurobiology of Disease 2011, 41:111-118.
3. Anonymous A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007, 68:20-28.
4. Anvret A., Westerlund M., Sydow O., Willows T., Lind C., Galter D., Belin A.C. Variations of the CAG trinucleotide repeat in DNA polymerase gamma (POLG1) is associated with Parkinson's disease in Sweden. Neuroscience Letters 2010, 485:117-120.
5. Ashley A.K., Hanneman W.H., Katoh T., Moreno J.A., Pollack A., Tjalkens R.B., Legare M.E. Analysis of targeted mutation in DJ-1 on cellular function in primary astrocytes. Toxicology Letters 2009, 184:186-191.
6. Barlow B.K., Lee D.W., Cory-Slechta D.A., Opanashuk L.A. Modulation of antioxidant defense systems by the environmental pesticide maneb in dopaminergic cells. Neurotoxicology 2005, 26:63-75.
7. Beal M.F. Mitochondria, oxidative damage, and inflammation in Parkinson's disease. Annals of the New York Academy of Sciences 2003, 991:120-131.
8. Benard G., Karbowski M. Mitochondrial fusion and division: regulation and role in cell viability. Seminars in Cell & Developmental Biology 2009, 20:365-374.
9. Bender A., Koch W., Elstner M., Schombacher Y., Bender J., Moeschl M., Gekeler F., Muller-Myhsok B., Gasser T., Tatsch K., Klopstock T. Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 2006, 67:1262-1264.
10. Bender A., Krishnan K.J., Morris C.M., Taylor G.A., Reeve A.K., Perry R.H., Jaros E., Hersheson J.S., Betts J., Klopstock T., Taylor R.W., Turnbull D.M. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Nature Genetics 2006, 38:515-517.
11. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nature Neuroscience 2000, 3:1301-1306.
12. Bian M., Liu J., Hong X., Yu M., Huang Y., Sheng Z., Fei J., Huang F. Overexpression of parkin ameliorates dopaminergic neurodegeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. PloS One 2012, 7:e39953.
13. Biskup S., West A.B. Zeroing in on LRRK2-linked pathogenic mechanisms in Parkinson's disease. Biochimica et Biophysica Acta 2009, 1792:625-633.
14. Biskup S., Moore D.J., Celsi F., Higashi S., West A.B., Andrabi S.A., Kurkinen K., Yu S.W., Savitt J.M., Waldvogel H.J., Faull R.L., Emson P.C., Torp R., Ottersen O.P., Dawson T.M., Dawson V.L. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Annals of Neurology 2006, 60:557-569.
15. Blackinton J., Lakshminarasimhan M., Thomas K.J., Ahmad R., Greggio E., Raza A.S., Cookson M.R., Wilson M.A. Formation of a stabilized cysteine sulfinic acid is critical for the mitochondrial function of the parkinsonism protein DJ-1. The Journal of Biological Chemistry 2009, 284:6476-6485.
16. Blin O., Desnuelle C., Rascol O., Borg M., Peyro Saint Paul H., Azulay J.P., Bille F., Figarella D., Coulom F., Pellissier J.F., et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy. Journal of the Neurological Sciences 1994, 125:95-101.
17. Bonci A., Grillner P., Mercuri N.B., Bernardi G. L-type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 1998, 18:6693-6703.
18. Bonifati V., Rizzu P., van Baren M.J., Schaap O., Breedveld G.J., Krieger E., Dekker M.C., Squitieri F., Ibanez P., Joosse M., van Dongen J.W., Vanacore N., van Swieten J.C., Brice A., Meco G., van Duijn C.M., Oostra B.A., Heutink P. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 2003, 299:256-259.
19. Brooks A.I., Chadwick C.A., Gelbard H.A., Cory-Slechta D.A., Federoff H.J. Paraquat elicited neurobehavioral syndrome caused by dopaminergic neuron loss. Brain Research 1999, 823:1-10.
20. Burte F., De Girolamo L.A., Hargreaves A.J., Billett E.E. Alterations in the mitochondrial proteome of neuroblastoma cells in response to complex 1 inhibition. Journal of Proteome Research 2011, 10:1974-1986.
21. Butler E.K., Voigt A., Lutz A.K., Toegel J.P., Gerhardt E., Karsten P., Falkenburger B., Reinartz A., Winklhofer K.F., Schulz J.B. The mitochondrial chaperone protein TRAP1 mitigates alpha-Synuclein toxicity. PLoS Genetics 2012, 8:e1002488.
22. Canet-Aviles R.M., Wilson M.A., Miller D.W., Ahmad R., McLendon C., Bandyopadhyay S., Baptista M.J., Ringe D., Petsko G.A., Cookson M.R. The Parkinson's disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proceedings of the National Academy of Sciences of the United States of America 2004, 101:9103-9108.
23. Cardoso S.M., Esteves A.R., Arduino D.M. Mitochondrial metabolic control of microtubule dynamics impairs the autophagic pathway in Parkinson's disease. Neuro-Degenerative Diseases 2012, 10:38-40.
24. Casarejos M.J., Menendez J., Solano R.M., Rodriguez-Navarro J.A., Garcia de Yebenes J., Mena M.A. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. Journal of Neurochemistry 2006, 97:934-946.
25. Chan P., DeLanney L.E., Irwin I., Langston J.W., Di Monte D. Rapid ATP loss caused by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mouse brain. Journal of Neurochemistry 1991, 57:348-351.
26. Chan C.S., Guzman J.N., Ilijic E., Mercer J.N., Rick C., Tkatch T., Meredith G.E., Surmeier D.J. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature 2007, 447:1081-1086.
27. Chen H., Chan D.C. Mitochondrial dynamics - fusion, fission, movement, and mitophagy - in neurodegenerative diseases. Human Molecular Genetics 2009, 18:R169-R176.
28. Chen L., Cagniard B., Mathews T., Jones S., Koh H.C., Ding Y., Carvey P.M., Ling Z., Kang U.J., Zhuang X. Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. The Journal of Biological Chemistry 2005, 280:21418-21426.
29. Chesselet M.F., Richter F., Zhu C., Magen I., Watson M.B., Subramaniam S.R. A progressive mouse model of Parkinson's disease: the Thy1-aSyn ("Line 61") mice. Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics 2012, 9:297-314.
30. Chinta S.J., Andersen J.K. Redox imbalance in Parkinson's disease. Biochimica et Biophysica Acta 2008, 1780:1362-1367.
31. Chiueh C.C., Markey S.P., Burns R.S., Johannessen J.N., Jacobowitz D.M., Kopin I.J. Neurochemical and behavioral effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in rat, guinea pig, and monkey. Psychopharmacology Bulletin 1984, 20:548-553.
32. Choi W.S., Kruse S.E., Palmiter R.D., Xia Z. Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:15136-15141.
33. Clark I.E., Dodson M.W., Jiang C., Cao J.H., Huh J.R., Seol J.H., Yoo S.J., Hay B.A., Guo M. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 2006, 441:1162-1166.
34. Cocheme H.M., Murphy M.P. Complex I is the major site of mitochondrial superoxide production by paraquat. The Journal of Biological Chemistry 2008, 283:1786-1798.
35. Cole N.B., Dieuliis D., Leo P., Mitchell D.C., Nussbaum R.L. Mitochondrial translocation of alpha-synuclein is promoted by intracellular acidification. Experimental Cell Research 2008, 314:2076-2089.
36. Conway K.A., Harper J.D., Lansbury P.T. Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nature Medicine 1998, 4:1318-1320.
37. Conway K.A., Lee S.J., Rochet J.C., Ding T.T., Williamson R.E., Lansbury P.T. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:571-576.
38. Cookson M.R., van der Brug M. Cell systems and the toxic mechanism(s) of alpha-synuclein. Experimental Neurology 2008, 209:5-11.
39. Costello S., Cockburn M., Bronstein J., Zhang X., Ritz B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. American Journal of Epidemiology 2009, 169:919-926.
40. Couzin J. Clinical research: testing a novel strategy against Parkinson's disease. Science 2007, 315:1778.
41. Darios F., Corti O., Lucking C.B., Hampe C., Muriel M.P., Abbas N., Gu W.J., Hirsch E.C., Rooney T., Ruberg M., Brice A. Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death. Human Molecular Genetics 2003, 12:517-526.
42. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
43. Davis G.C., Williams A.C., Markey S.P., Ebert M.H., Caine E.D., Reichert C.M., Kopin I.J. Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Research 1979, 1:249-254.
44. Dawson T.M. Parkin and defective ubiquitination in Parkinson's disease. Journal of Neural Transmission 2006, 70(Suppl.):209-213.
45. Deng H., Dodson M.W., Huang H., Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:14503-14508.
46. Desai V.G., Feuers R.J., Hart R.W., Ali S.F. MPP(+)-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport. Brain Research 1996, 715:1-8.
47. Devi L., Raghavendran V., Prabhu B.M., Avadhani N.G., Anandatheerthavarada H.K. Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. The Journal of Biological Chemistry 2008, 283:9089-9100.
48. Diedrich M., Kitada T., Nebrich G., Koppelstaetter A., Shen J., Zabel C., Klose J., Mao L. Brain region specific mitophagy capacity could contribute to selective neuronal vulnerability in Parkinson's disease. Proteome Science 2011, 9:59.
49. Domico L.M., Zeevalk G.D., Bernard L.P., Cooper K.R. Acute neurotoxic effects of mancozeb and maneb in mesencephalic neuronal cultures are associated with mitochondrial dysfunction. Neurotoxicology 2006, 27:816-825.
50. Doss-Pepe E.W., Chen L., Madura K. Alpha-synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. The Journal of Biological Chemistry 2005, 280:16619-16624.
51. Edwards T.L., Scott W.K., Almonte C., Burt A., Powell E.H., Beecham G.W., Wang L., Zuchner S., Konidari I., Wang G., Singer C., Nahab F., Scott B., Stajich J.M., Pericak-Vance M., Haines J., Vance J.M., Martin E.R. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Annals of Human Genetics 2010, 74:97-109.
52. Ekstrand M.I., Terzioglu M., Galter D., Zhu S., Hofstetter C., Lindqvist E., Thams S., Bergstrand A., Hansson F.S., Trifunovic A., Hoffer B., Cullheim S., Mohammed A.H., Olson L., Larsson N.G. Progressive parkinsonism in mice with respiratory-chain-deficient dopamine neurons. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:1325-1330.
53. Elm J.J. Design innovations and baseline findings in a long-term Parkinson's trial: the National Institute of Neurological Disorders and Stroke Exploratory Trials in Parkinson's Disease Long-Term Study-1. Movement Disorders:Official Journal of the Movement Disorder Society 2012, 27:1513-1521.
54. Exner N., Treske B., Paquet D., Holmstrom K., Schiesling C., Gispert S., Carballo-Carbajal I., Berg D., Hoepken H.H., Gasser T., Kruger R., Winklhofer K.F., Vogel F., Reichert A.S., Auburger G., Kahle P.J., Schmid B., Haass C. Loss-of-function of human PINK1 results in mitochondrial pathology and can be rescued by parkin. The Journal of Neuroscience:the Official Journal of the Society for Neuroscience 2007, 27:12413-12418.
55. 2 and ATP production and on dopamine and DOPAC in the striatum. Journal of Physiology and Biochemistry 1999, 55:325-331.
56. Fallon L., Belanger C.M., Corera A.T., Kontogiannea M., Regan-Klapisz E., Moreau F., Voortman J., Haber M., Rouleau G., Thorarinsdottir T., Brice A., van Bergen En Henegouwen P.M., Fon E.A. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI(3)K-Akt signalling. Nature Cell Biology 2006, 8:834-842.
57. Filosto M., Mancuso M., Nishigaki Y., Pancrudo J., Harati Y., Gooch C., Mankodi A., Bayne L., Bonilla E., Shanske S., Hirano M., DiMauro S. Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma. Archives of Neurology 2003, 60:1279-1284.
58. Fleming S.M., Salcedo J., Fernagut P.O., Rockenstein E., Masliah E., Levine M.S., Chesselet M.F. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 2004, 24:9434-9440.
59. Fornai F., Schluter O.M., Lenzi P., Gesi M., Ruffoli R., Ferrucci M., Lazzeri G., Busceti C.L., Pontarelli F., Battaglia G., Pellegrini A., Nicoletti F., Ruggieri S., Paparelli A., Sudhof T.C. Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:3413-3418.
60. Forno L.S., DeLanney L.E., Irwin I., Langston J.W. Similarities and differences between MPTP-induced parkinsonsim and Parkinson's disease. Neuropathologic considerations. Advances in Neurology 1993, 60:600-608.
61. Fredenburg R.A., Rospigliosi C., Meray R.K., Kessler J.C., Lashuel H.A., Eliezer D., Lansbury P.T. The impact of the E46K mutation on the properties of alpha-synuclein in its monomeric and oligomeric states. Biochemistry 2007, 46:7107-7118.
62. Gandhi S., Muqit M.M., Stanyer L., Healy D.G., Abou-Sleiman P.M., Hargreaves I., Heales S., Ganguly M., Parsons L., Lees A.J., Latchman D.S., Holton J.L., Wood N.W., Revesz T. PINK1 protein in normal human brain and Parkinson's disease. Brain: a Journal of Neurology 2006, 129:1720-1731.
63. Gandhi P.N., Chen S.G., Wilson-Delfosse A.L. Leucine-rich repeat kinase 2 (LRRK2): a key player in the pathogenesis of Parkinson's disease. Journal of Neuroscience Research 2009, 87:1283-1295.
64. Gandhi S., Vaarmann A., Yao Z., Duchen M.R., Wood N.W., Abramov A.Y. Dopamine induced neurodegeneration in a PINK1 model of Parkinson's disease. PloS One 2012, 7:e37564.
65. Gatto N.M., Rhodes S.L., Manthripragada A.D., Bronstein J., Cockburn M., Farrer M., Ritz B. Alpha-Synuclein gene may interact with environmental factors in increasing risk of Parkinson's disease. Neuroepidemiology 2010, 35:191-195.
66. Gautam A.H., Zeevalk G.D. Characterization of reduced and oxidized dopamine and 3,4-dihydrophenylacetic acid, on brain mitochondrial electron transport chain activities. Biochimica et Biophysica Acta 2011, 1807:819-828.
67. Gautier C.A., Kitada T., Shen J. Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:11364-11369.
68. Giaime E., Yamaguchi H., Gautier C.A., Kitada T., Shen J. Loss of DJ-1 does not affect mitochondrial respiration but increases ROS production and mitochondrial permeability transition pore opening. PloS One 2012, 7:e40501.
69. Gloeckner C.J., Kinkl N., Schumacher A., Braun R.J., O'Neill E., Meitinger T., Kolch W., Prokisch H., Ueffing M. The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Human Molecular Genetics 2006, 15:223-232.
70. Goldberg M.S., Pisani A., Haburcak M., Vortherms T.A., Kitada T., Costa C., Tong Y., Martella G., Tscherter A., Martins A., Bernardi G., Roth B.L., Pothos E.N., Calabresi P., Shen J. Nigrostriatal dopaminergic deficits and hypokinesia caused by inactivation of the familial Parkinsonism-linked gene DJ-1. Neuron 2005, 45:489-496.
71. Gomez-Lazaro M., Bonekamp N.A., Galindo M.F., Jordan J., Schrader M. 6-Hydroxydopamine (6-OHDA) induces Drp1-dependent mitochondrial fragmentation in SH-SY5Y cells. Free Radical Biology & Medicine 2008, 44:1960-1969.
72. Good C.H., Hoffman A.F., Hoffer B.J., Chefer V.I., Shippenberg T.S., Backman C.M., Larsson N.G., Olson L., Gellhaar S., Galter D., Lupica C.R. Impaired nigrostriatal function precedes behavioral deficits in a genetic mitochondrial model of Parkinson's disease. FASEB Journal:Official Publication of the Federation of American Societies for Experimental Biology 2011, 25:1333-1344.
73. Grace A.A., Bunney B.S. Intracellular and extracellular electrophysiology of nigral dopaminergic neurons - 2 Action potential generating mechanisms and morphological correlates. Neuroscience 1983, 10:317-331.
74. Greene J.C., Whitworth A.J., Kuo I., Andrews L.A., Feany M.B., Pallanck L.J. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:4078-4083.
75. Greggio E., Jain S., Kingsbury A., Bandopadhyay R., Lewis P., Kaganovich A., van der Brug M.P., Beilina A., Blackinton J., Thomas K.J., Ahmad R., Miller D.W., Kesavapany S., Singleton A., Lees A., Harvey R.J., Harvey K., Cookson M.R. Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiology of Disease 2006, 23:329-341.
76. Guzman J.N., Sanchez-Padilla J., Wokosin D., Kondapalli J., Ilijic E., Schumacker P.T., Surmeier D.J. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Nature 2010, 468:696-700.
77. Haas R.H., Nasirian F., Nakano K., Ward D., Pay M., Hill R., Shults C.W. Low platelet mitochondrial complex I and complex II/III activity in early untreated Parkinson's disease. Annals of Neurology 1995, 37:714-722.
78. Hald A., Lotharius J. Oxidative stress and inflammation in Parkinson's disease: is there a causal link?. Experimental Neurology 2005, 193:279-290.
79. Hampe C., Ardila-Osorio H., Fournier M., Brice A., Corti O. Biochemical analysis of Parkinson's disease-causing variants of Parkin, an E3 ubiquitin-protein ligase with monoubiquitylation capacity. Human Molecular Genetics 2006, 15:2059-2075.
80. Hantraye P., Varastet M., Peschanski M., Riche D., Cesaro P., Willer J.C., Maziere M. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 1993, 53:169-178.
81. Hantraye P., Brouillet E., Ferrante R., Palfi S., Dolan R., Matthews R.T., Beal M.F. Inhibition of neuronal nitric oxide synthase prevents MPTP-induced parkinsonism in baboons. Nature Medicine 1996, 2:1017-1021.
82. Haque M.E., Thomas K.J., D'Souza C., Callaghan S., Kitada T., Slack R.S., Fraser P., Cookson M.R., Tandon A., Park D.S. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:1716-1721.
83. Hartmann A., Hunot S., Michel P.P., Muriel M.P., Vyas S., Faucheux B.A., Mouatt-Prigent A., Turmel H., Srinivasan A., Ruberg M., Evan G.I., Agid Y., Hirsch E.C. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2000, 97:2875-2880.
84. Hartmann A., Michel P.P., Troadec J.D., Mouatt-Prigent A., Faucheux B.A., Ruberg M., Agid Y., Hirsch E.C. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease?. Journal of Neurochemistry 2001, 76:1785-1793.
85. Hartmann A., Troadec J.D., Hunot S., Kikly K., Faucheux B.A., Mouatt-Prigent A., Ruberg M., Agid Y., Hirsch E.C. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. The Journal of neuroscience:the official journal of the Society for Neuroscience 2001, 21:2247-2255.
86. Hasegawa E., Takeshige K., Oishi T., Murai Y., Minakami S. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochemical and Biophysical Research Communications 1990, 170:1049-1055.
87. Hattori N., Tanaka M., Ozawa T., Mizuno Y. Immunohistochemical studies on complexes I, II, III, and IV of mitochondria in Parkinson's disease. Annals of Neurology 1991, 30:563-571.
88. Heikkila R.E., Hess A., Duvoisin R.C. Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice. Science 1984, 224:1451-1453.
89. Henn I.H., Bouman L., Schlehe J.S., Schlierf A., Schramm J.E., Wegener E., Nakaso K., Culmsee C., Berninger B., Krappmann D., Tatzelt J., Winklhofer K.F. Parkin mediates neuroprotection through activation of IkappaB kinase/nuclear factor-kappaB signaling. The Journal of Neuroscience:the Official Journal of the Society for Neuroscience 2007, 27:1868-1878.
90. Heo J.Y., Park J.H., Kim S.J., Seo K.S., Han J.S., Lee S.H., Kim J.M., Park J.I., Park S.K., Lim K., Hwang B.D., Shong M., Kweon G.R. DJ-1 null dopaminergic neuronal cells exhibit defects in mitochondrial function and structure: involvement of mitochondrial complex I assembly. PloS One 2012, 7:e32629.
91. Hoang T., Choi D.K., Nagai M., Wu D.C., Nagata T., Prou D., Wilson G.L., Vila M., Jackson-Lewis V., Dawson V.L., Dawson T.M., Chesselet M.F., Przedborski S. Neuronal NOS and cyclooxygenase-2 contribute to DNA damage in a mouse model of Parkinson disease. Free Radical Biology & Medicine 2009, 47:1049-1056.
92. Hoepken H.H., Gispert S., Morales B., Wingerter O., Del Turco D., Mulsch A., Nussbaum R.L., Muller K., Drose S., Brandt U., Deller T., Wirth B., Kudin A.P., Kunz W.S., Auburger G. Mitochondrial dysfunction, peroxidation damage and changes in glutathione metabolism in PARK6. Neurobiology of Disease 2007, 25:401-411.
93. Hoppins S., Nunnari J. The molecular mechanism of mitochondrial fusion. Biochimica et Biophysica Acta 2009, 1793:20-26.
94. Huang Y., Rowe D.B., Halliday G.M. Interaction between α-Synuclein and tau genotypes and the progression of parkinson's disease. Journal of Parkinson's Disease 2011, 1:271-276.
95. Humphrey D.M., Parsons R.B., Ludlow Z.N., Riemensperger T., Esposito G., Verstreken P., Jacobs H.T., Birman S., Hirth F. Alternative oxidase rescues mitochondria-mediated dopaminergic cell loss in Drosophila. Human Molecular Genetics 2012, 21:2698-2712.
96. Hyun D.H., Lee M., Halliwell B., Jenner P. Effect of overexpression of wild-type or mutant parkin on the cellular response induced by toxic insults. Journal of Neuroscience Research 2005, 82:232-244.
97. Iaccarino C., Crosio C., Vitale C., Sanna G., Carri M.T., Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Human Molecular Genetics 2007, 16:1319-1326.
98. Irrcher I., Aleyasin H., Seifert E.L., Hewitt S.J., Chhabra S., Phillips M., Lutz A.K., Rousseaux M.W., Bevilacqua L., Jahani-Asl A., Callaghan S., MacLaurin J.G., Winklhofer K.F., Rizzu P., Rippstein P., Kim R.H., Chen C.X., Fon E.A., Slack R.S., Harper M.E., McBride H.M., Mak T.W., Park D.S. Loss of the Parkinson's disease-linked gene DJ-1 perturbs mitochondrial dynamics. Human Molecular Genetics 2010, 19:3734-3746.
99. Ishihara N., Nomura M., Jofuku A., Kato H., Suzuki S.O., Masuda K., Otera H., Nakanishi Y., Nonaka I., Goto Y., Taguchi N., Morinaga H., Maeda M., Takayanagi R., Yokota S., Mihara K. Mitochondrial fission factor Drp1 is essential for embryonic development and synapse formation in mice. Nature Cell Biology 2009, 11:958-966.
100. Isobe C., Abe T., Terayama Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neuroscience Letters 2010, 469:159-163.
101. Jones G.M., Vale J.A. Mechanisms of toxicity, clinical features, and management of diquat poisoning: a review. Journal of Toxicology Clinical Toxicology 2000, 38:123-128.
102. Junn E., Jang W.H., Zhao X., Jeong B.S., Mouradian M.M. Mitochondrial localization of DJ-1 leads to enhanced neuroprotection. Journal of Neuroscience Research 2009, 87:123-129.
103. Kachroo A., Irizarry M.C., Schwarzschild M.A. Caffeine protects against combined paraquat and maneb-induced dopaminergic neuron degeneration. Experimental Neurology 2010, 223:657-661.
104. Keeney P.M., Xie J., Capaldi R.A., Bennett J.P. Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. The Journal of Neuroscience:the Official Journal of the Society for Neuroscience 2006, 26:5256-5264.
105. Kim R.H., Smith P.D., Aleyasin H., Hayley S., Mount M.P., Pownall S., Wakeham A., You-Ten A.J., Kalia S.K., Horne P., Westaway D., Lozano A.M., Anisman H., Park D.S., Mak T.W. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:5215-5220.
106. Kitada T., Asakawa S., Hattori N., Matsumine H., Yamamura Y., Minoshima S., Yokochi M., Mizuno Y., Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998, 392:605-608.
107. Kitada T., Pisani A., Porter D.R., Yamaguchi H., Tscherter A., Martella G., Bonsi P., Zhang C., Pothos E.N., Shen J. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:11441-11446.
108. Klein C., Schlossmacher M.G. The genetics of Parkinson disease: implications for neurological care. Nature Clinical Practice Neurology 2006, 2:136-146.
109. Klivenyi P., Siwek D., Gardian G., Yang L., Starkov A., Cleren C., Ferrante R.J., Kowall N.W., Abeliovich A., Beal M.F. Mice lacking alpha-synuclein are resistant to mitochondrial toxins. Neurobiology of Disease 2006, 21:541-548.
110. Knott A.B., Bossy-Wetzel E. Impairing the mitochondrial fission and fusion balance: a new mechanism of neurodegeneration. Annals of the New York Academy of Sciences 2008, 1147:283-292.
111. Kraytsberg Y., Kudryavtseva E., McKee A.C., Geula C., Kowall N.W., Khrapko K. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Nature Genetics 2006, 38:518-520.
112. Krebiehl G., Ruckerbauer S., Burbulla L.F., Kieper N., Maurer B., Waak J., Wolburg H., Gizatullina Z., Gellerich F.N., Woitalla D., Riess O., Kahle P.J., Proikas-Cezanne T., Kruger R. Reduced basal autophagy and impaired mitochondrial dynamics due to loss of Parkinson's disease-associated protein DJ-1. PloS One 2010, 5:e9367.
113. Krige D., Carroll M.T., Cooper J.M., Marsden C.D., Schapira A.H. Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group. Annals of Neurology 1992, 32:782-788.
114. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nature Genetics 1998, 18:106-108.
115. Kruse S.E., Watt W.C., Marcinek D.J., Kapur R.P., Schenkman K.A., Palmiter R.D. Mice with mitochondrial complex I deficiency develop a fatal encephalomyopathy. Cell Metabolism 2008, 7:312-320.
116. Kuroda Y., Mitsui T., Kunishige M., Shono M., Akaike M., Azuma H., Matsumoto T. Parkin enhances mitochondrial biogenesis in proliferating cells. Human Molecular Genetics 2006, 15:883-895.
117. Kwon H.J., Heo J.Y., Shim J.H., Park J.H., Seo K.S., Ryu M.J., Han J.S., Shong M., Son J.H., Kweon G.R. DJ-1 mediates paraquat-induced dopaminergic neuronal cell death. Toxicology Letters 2011, 202:85-92.
118. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
119. Langston J.W., Irwin I., Langston E.B., Forno L.S. 1-Methyl-4-phenylpyridinium ion (MPP+): identification of a metabolite of MPTP, a toxin selective to the substantia nigra. Neuroscience Letters 1984, 48:87-92.
120. Langston J.W., Forno L.S., Tetrud J., Reeves A.G., Kaplan J.A., Karluk D. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure. Annals of Neurology 1999, 46:598-605.
121. Lansbury P.T., Lashuel H.A. A century-old debate on protein aggregation and neurodegeneration enters the clinic. Nature 2006, 443:774-779.
122. Li W.W., Yang R., Guo J.C., Ren H.M., Zha X.L., Cheng J.S., Cai D.F. Localization of alpha-synuclein to mitochondria within midbrain of mice. Neuroreport 2007, 18:1543-1546.
123. Liang C.L., Wang T.T., Luby-Phelps K., German D.C. Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson's disease. Experimental Neurology 2007, 203:370-380.
124. Lim K.L., Chew K.C., Tan J.M., Wang C., Chung K.K., Zhang Y., Tanaka Y., Smith W., Engelender S., Ross C.A., Dawson V.L., Dawson T.M. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: implications for Lewy body formation. The Journal of Neuroscience:the Official Journal of the Society for Neuroscience 2005, 25:2002-2009.
125. Luoma P., Melberg A., Rinne J.O., Kaukonen J.A., Nupponen N.N., Chalmers R.M., Oldfors A., Rautakorpi I., Peltonen L., Majamaa K., Somer H., Suomalainen A. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Lancet 2004, 364:875-882.
126. Ma L., Cao T.T., Kandpal G., Warren L., Fred Hess J., Seabrook G.R., Ray W.J. Genome-wide microarray analysis of the differential neuroprotective effects of antioxidants in neuroblastoma cells overexpressing the familial Parkinson's disease alpha-synuclein A53T mutation. Neurochemical Research 2010, 35:130-142.
127. Maj M.C., Tkachyova I., Patel P., Addis J.B., Mackay N., Levandovskiy V., Lee J., Lang A.E., Cameron J.M., Robinson B.H. Oxidative stress alters the regulatory control of p66Shc and Akt in PINK1 deficient cells. Biochemical and Biophysical Research Communications 2010, 399:331-335.
128. Manfredsson F.P., Burger C., Sullivan L.F., Muzyczka N., Lewin A.S., Mandel R.J. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Experimental Neurology 2007, 207:289-301.
129. Markey S.P., Johannessen J.N., Chiueh C.C., Burns R.S., Herkenham M.A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984, 311:464-467.
130. Martin L.J., Pan Y., Price A.C., Sterling W., Copeland N.G., Jenkins N.A., Price D.L., Lee M.K. Parkinson's disease alpha-synuclein transgenic mice develop neuronal mitochondrial degeneration and cell death. The Journal of Neuroscience:the Official Journal of the Society for Neuroscience 2006, 26:41-50.
131. Mata I.F., Wedemeyer W.J., Farrer M.J., Taylor J.P., Gallo K.A. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends in Neurosciences 2006, 29:286-293.
132. Mattson M.P., Gleichmann M., Cheng A. Mitochondria in neuroplasticity and neurological disorders. Neuron 2008, 60:748-766.
133. McCormack A.L., Thiruchelvam M., Manning-Bog A.B., Thiffault C., Langston J.W., Cory-Slechta D.A., Di Monte D.A. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiology of Disease 2002, 10:119-127.
134. McDowell K., Chesselet M.F. Animal models of the non-motor features of Parkinson's disease. Neurobiology of Disease 2012, 46:597-606.
135. Meco G., Bonifati V., Vanacore N., Fabrizio E. Parkinsonism after chronic exposure to the fungicide maneb (manganese ethylene-bis-dithiocarbamate). Scandinavian Journal of Work, Environment & Health 1994, 20:301-305.
136. Meuer K., Suppanz I.E., Lingor P., Planchamp V., Goricke B., Fichtner L., Braus G.H., Dietz G.P., Jakobs S., Bahr M., Weishaupt J.H. Cyclin-dependent kinase 5 is an upstream regulator of mitochondrial fission during neuronal apoptosis. Cell Death and Differentiation 2007, 14:651-661.
137. Mizuno Y., Ohta S., Tanaka M., Takamiya S., Suzuki K., Sato T., Oya H., Ozawa T., Kagawa Y. Deficiencies in complex I subunits of the respiratory chain in Parkinson's disease. Biochemical and Biophysical Research Communications 1989, 163:1450-1455.
138. Mollace V., Iannone M., Muscoli C., Palma E., Granato T., Rispoli V., Nistico R., Rotiroti D., Salvemini D. The role of oxidative stress in paraquat-induced neurotoxicity in rats: protection by non peptidyl superoxide dismutase mimetic. Neuroscience Letters 2003, 335:163-166.
139. Moore D.J., Zhang L., Troncoso J., Lee M.K., Hattori N., Mizuno Y., Dawson T.M., Dawson V.L. Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress. Human Molecular Genetics 2005, 14:71-84.
140. Moratalla R., Quinn B., DeLanney L.E., Irwin I., Langston J.W., Graybiel A.M. Differential vulnerability of primate caudate-putamen and striosome-matrix dopamine systems to the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proceedings of the National Academy of Sciences of the United States of America 1992, 89:3859-3863.
141. Morato G.S., Lemos T., Takahashi R.N. Acute exposure to maneb alters some behavioral functions in the mouse. Neurotoxicology and Teratology 1989, 11:421-425.
142. Mortiboys H., Johansen K.K., Aasly J.O., Bandmann O. Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2. Neurology 2010, 75:2017-2020.
143. Mosharov E.V., Larsen K.E., Kanter E., Phillips K.A., Wilson K., Schmitz Y., Krantz D.E., Kobayashi K., Edwards R.H., Sulzer D. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Neuron 2009, 62:218-229.
144. Muftuoglu M., Elibol B., Dalmizrak O., Ercan A., Kulaksiz G., Ogus H., Dalkara T., Ozer N. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Movement Disorders:Official Journal of the Movement Disorder Society 2004, 19:544-548.
145. Mukhopadhyay D., Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007, 315:201-205.
146. Muller T., Buttner T., Gholipour A.F., Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neuroscience Letters 2003, 341:201-204.
147. Murakami T., Shoji M., Imai Y., Inoue H., Kawarabayashi T., Matsubara E., Harigaya Y., Sasaki A., Takahashi R., Abe K. Pael-R is accumulated in Lewy bodies of Parkinson's disease. Annals of Neurology 2004, 55:439-442.
148. Murphy M.P. How mitochondria produce reactive oxygen species. The Biochemical Journal 2009, 417:1-13.
149. Mytilineou C., Werner P., Molinari S., Di Rocco A., Cohen G., Yahr M.D. Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section 1994, 8:223-228.
150. Nakamura K., Nemani V.M., Wallender E.K., Kaehlcke K., Ott M., Edwards R.H. Optical reporters for the conformation of alpha-synuclein reveal a specific interaction with mitochondria. The Journal of Neuroscience:the Official Journal of the Society for Neuroscience 2008, 28:12305-12317.
151. Narendra D., Tanaka A., Suen D.F., Youle R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. The Journal of Cell Biology 2008, 183:795-803.
152. Narendra D.P., Jin S.M., Tanaka A., Suen D.F., Gautier C.A., Shen J., Cookson M.R., Youle R.J. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biology 2010, 8:e1000298.
153. Nicholls D.G. Oxidative stress and energy crises in neuronal dysfunction. Annals of the New York Academy of Sciences 2008, 1147:53-60.
154. Nicklas W.J., Vyas I., Heikkila R.E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sciences 1985, 36:2503-2508.
155. Niu J., Yu M., Wang C., Xu Z. Leucine-rich repeat kinase 2 disturbs mitochondrial dynamics via dynamin-like protein. Journal of Neurochemistry 2012, 122:650-658.
156. Norris E.H., Uryu K., Leight S., Giasson B.I., Trojanowski J.Q., Lee V.M. Pesticide exposure exacerbates alpha-synucleinopathy in an A53T transgenic mouse model. The American Journal of Pathology 2007, 170:658-666.
157. Ossowska K., Wardas J., Smialowska M., Kuter K., Lenda T., Wieronska J.M., Zieba B., Nowak P., Dabrowska J., Bortel A., Kwiecinski A., Wolfarth S. A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease?. The European Journal of Neuroscience 2005, 22:1294-1304.
158. Ozawa T. Oxidative damage and fragmentation of mitochondrial DNA in cellular apoptosis. Bioscience Reports 1997, 17:237-250.
159. Paisan-Ruiz C., Jain S., Evans E.W., Gilks W.P., Simon J., van der Brug M., Lopez de Munain A., Aparicio S., Gil A.M., Khan N., Johnson J., Martinez J.R., Nicholl D., Carrera I.M., Pena A.S., de Silva R., Lees A., Marti-Masso J.F., Perez-Tur J., Wood N.W., Singleton A.B. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
160. Palacino J.J., Sagi D., Goldberg M.S., Krauss S., Motz C., Wacker M., Klose J., Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. The Journal of Biological Chemistry 2004, 279:18614-18622.
161. Parihar M.S., Parihar A., Fujita M., Hashimoto M., Ghafourifar P. Mitochondrial association of alpha-synuclein causes oxidative stress. Cellular and Molecular Life Sciences:CMLS 2008, 65:1272-1284.
162. Park J., Lee S.B., Lee S., Kim Y., Song S., Kim S., Bae E., Kim J., Shong M., Kim J.M., Chung J. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 2006, 441:1157-1161.
163. Park J., Lee G., Chung J. The PINK1-Parkin pathway is involved in the regulation of mitochondrial remodeling process. Biochemical and Biophysical Research Communications 2009, 378:518-523.
164. Parker W.D., Parks J.K., Swerdlow R.H. Complex I deficiency in Parkinson's disease frontal cortex. Brain Research 2008, 1189:215-218.
165. Paterna J.C., Leng A., Weber E., Feldon J., Bueler H. DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Molecular Therapy:the Journal of the American Society of Gene Therapy 2007, 15:698-704.
166. Pennathur S., Jackson-Lewis V., Przedborski S., Heinecke J.W. Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o,o'-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. The Journal of Biological Chemistry 1999, 274:34621-34628.
167. Perez F.A., Palmiter R.D. Parkin-deficient mice are not a robust model of parkinsonism. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:2174-2179.
168. Perier C., Tieu K., Guegan C., Caspersen C., Jackson-Lewis V., Carelli V., Martinuzzi A., Hirano M., Przedborski S., Vila M. Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:19126-19131.
169. Perier C., Bove J., Wu D.C., Dehay B., Choi D.K., Jackson-Lewis V., Rathke-Hartlieb S., Bouillet P., Strasser A., Schulz J.B., Przedborski S., Vila M. Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:8161-8166.
170. Periquet M., Corti O., Jacquier S., Brice A. Proteomic analysis of parkin knockout mice: alterations in energy metabolism protein handling and synaptic function. Journal of Neurochemistry 2005, 95:1259-1276.
171. Pesah Y., Pham T., Burgess H., Middlebrooks B., Verstreken P., Zhou Y., Harding M., Bellen H., Mardon G. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004, 131:2183-2194.
172. Petit A., Kawarai T., Paitel E., Sanjo N., Maj M., Scheid M., Chen F., Gu Y., Hasegawa H., Salehi-Rad S., Wang L., Rogaeva E., Fraser P., Robinson B., St George-Hyslop P., Tandon A. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. The Journal of Biological Chemistry 2005, 280:34025-34032.
173. Piao Y., Kim H.G., Oh M.S., Pak Y.K. Overexpression of TFAM, NRF-1 and myr-AKT protects the MPP(+)-induced mitochondrial dysfunctions in neuronal cells. Biochimica et Biophysica Acta 2012, 1820:577-585.
174. Piccoli C., Sardanelli A., Scrima R., Ripoli M., Quarato G., D'Aprile A., Bellomo F., Scacco S., De Michele G., Filla A., Iuso A., Boffoli D., Capitanio N., Papa S. Mitochondrial respiratory dysfunction in familiar parkinsonism associated with PINK1 mutation. Neurochemical Research 2008, 33:2565-2574.
175. Ping H.X., Shepard P.D. Apamin-sensitive Ca(2+)-activated K+ channels regulate pacemaker activity in nigral dopamine neurons. Neuroreport 1996, 7:809-814.
176. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
177. Poole A.C., Thomas R.E., Andrews L.A., McBride H.M., Whitworth A.J., Pallanck L.J. The PINK1/Parkin pathway regulates mitochondrial morphology. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:1638-1643.
178. Poon H.F., Frasier M., Shreve N., Calabrese V., Wolozin B., Butterfield D.A. Mitochondrial associated metabolic proteins are selectively oxidized in A30P alpha-synuclein transgenic mice - a model of familial Parkinson's disease. Neurobiology of Disease 2005, 18:492-498.
179. Prasad K., Winnik B., Thiruchelvam M.J., Buckley B., Mirochnitchenko O., Richfield E.K. Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain. Environmental Health Perspectives 2007, 115:1448-1453.
180. Pridgeon J.W., Olzmann J.A., Chin L.S., Li L. PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1. PLoS Biology 2007, 5:e172.
181. Przedborski S., Kostic V., Jackson-Lewis V., Naini A.B., Simonetti S., Fahn S., Carlson E., Epstein C.J., Cadet J.L. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity. The Journal of neuroscience:the official journal of the Society for Neuroscience 1992, 12:1658-1667.
182. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:4565-4571.
183. Puopolo M., Raviola E., Bean B.P. Roles of subthreshold calcium current and sodium current in spontaneous firing of mouse midbrain dopamine neurons. The Journal of Neuroscience:the Official Journal of the Society for Neuroscience 2007, 27:645-656.
184. Ramsay R.R., Salach J.I., Dadgar J., Singer T.P. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochemical and Biophysical Research Communications 1986, 135:269-275.
185. Reddy P.H., Reddy T.P., Manczak M., Calkins M.J., Shirendeb U., Mao P. Dynamin-related protein 1 and mitochondrial fragmentation in neurodegenerative diseases. Brain Research Reviews 2011, 67:103-118.
186. Reeve A.K., Krishnan K.J., Turnbull D. Mitochondrial DNA mutations in disease, aging, and neurodegeneration. Annals of the New York Academy of Sciences 2008, 1147:21-29.
187. Richardson J.R., Quan Y., Sherer T.B., Greenamyre J.T., Miller G.W. Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicological Sciences: an Official Journal of the Society of Toxicology 2005, 88:193-201.
188. Richter C., Park J.W., Ames B.N. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:6465-6467.
189. Ritz B.R., Manthripragada A.D., Costello S., Lincoln S.J., Farrer M.J., Cockburn M., Bronstein J. Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environmental Health Perspectives 2009, 117:964-969.
190. Ritz B., Rhodes S.L., Bordelon Y., Bronstein J. Alpha-Synuclein genetic variants predict faster motor symptom progression in idiopathic Parkinson disease. PloS One 2012, 7:e36199.
191. Roede J.R., Hansen J.M., Go Y.M., Jones D.P. Maneb and paraquat-mediated neurotoxicity: involvement of peroxiredoxin/thioredoxin system. Toxicological Sciences: an Official Journal of the Society of Toxicology 2011, 121:368-375.
192. Romo R., Schultz W. Dopamine neurons of the monkey midbrain: contingencies of responses to active touch during self-initiated arm movements. Journal of Neurophysiology 1990, 63:592-606.
193. Rosen K.M., Veereshwarayya V., Moussa C.E., Fu Q., Goldberg M.S., Schlossmacher M.G., Shen J., Querfurth H.W. Parkin protects against mitochondrial toxins and beta-amyloid accumulation in skeletal muscle cells. The Journal of Biological Chemistry 2006, 281:12809-12816.
194. Saini N., Oelhafen S., Hua H., Georgiev O., Schaffner W., Bueler H. Extended lifespan of Drosophila parkin mutants through sequestration of redox-active metals and enhancement of anti-oxidative pathways. Neurobiology of Disease 2010, 40:82-92.
195. Saint-Pierre M., Tremblay M.E., Sik A., Gross R.E., Cicchetti F. Temporal effects of paraquat/maneb on microglial activation and dopamine neuronal loss in older rats. Journal of Neurochemistry 2006, 98:760-772.
196. Schapira A.H. Mitochondrial pathology in Parkinson's disease. The Mount Sinai Journal of Medicine, New York 2011, 78:872-881.
197. Schapira A.H., Cooper J.M., Dexter D., Jenner P., Clark J.B., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989, 1:1269.
198. Schapira A.H., Cooper J.M., Dexter D., Clark J.B., Jenner P., Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. Journal of Neurochemistry 1990, 54:823-827.
199. Schon E.A., Przedborski S. Mitochondria: the next (neurode)generation. Neuron 2011, 70:1033-1053.
200. Shavali S., Brown-Borg H.M., Ebadi M., Porter J. Mitochondrial localization of alpha-synuclein protein in alpha-synuclein overexpressing cells. Neuroscience Letters 2008, 439:125-128.
201. Sherer T.B., Betarbet R., Testa C.M., Seo B.B., Richardson J.R., Kim J.H., Miller G.W., Yagi T., Matsuno-Yagi A., Greenamyre J.T. Mechanism of toxicity in rotenone models of Parkinson's disease. The Journal of Neuroscience: the Official Journal of the Society for Neuroscience 2003, 23:10756-10764.
202. Shimizu K., Matsubara K., Ohtaki K., Fujimaru S., Saito O., Shiono H. Paraquat induces long-lasting dopamine overflow through the excitotoxic pathway in the striatum of freely moving rats. Brain Research 2003, 976:243-252.
203. Shimura H., Hattori N., Kubo S., Mizuno Y., Asakawa S., Minoshima S., Shimizu N., Iwai K., Chiba T., Tanaka K., Suzuki T. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nature Genetics 2000, 25:302-305.
204. Shults C.W., Beal M.F., Fontaine D., Nakano K., Haas R.H. Absorption, tolerability, and effects on mitochondrial activity of oral coenzyme Q10 in parkinsonian patients. Neurology 1998, 50:793-795.
205. Silva B.A., Breydo L., Fink A.L., Uversky V.N. Agrochemicals, alpha-Synuclein, and Parkinson's Disease. Molecular Neurobiology 2013, 47(2):598-612.
206. Silvestri L., Caputo V., Bellacchio E., Atorino L., Dallapiccola B., Valente E.M., Casari G. Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism. Human Molecular Genetics 2005, 14:3477-3492.
207. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., Gwinn-Hardy K. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
208. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neuroscience 2006, 9:1231-1233.
209. Song D.D., Shults C.W., Sisk A., Rockenstein E., Masliah E Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Experimental Neurology 2004, 186:158-172.
210. Sonia Angeline M., Chaterjee P., Anand K., Ambasta R.K., Kumar P. Rotenone-induced parkinsonism elicits behavioral impairments and differential expression of parkin, heat shock proteins and caspases in the rat. Neuroscience 2012, 220:291-301.
211. Soubannier V., McBride H.M. Positioning mitochondrial plasticity within cellular signaling cascades. Biochimica et Biophysica Acta 2009, 1793:154-170.
212. Spillantini M.G., Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Annals of the New York Academy of Sciences 2000, 920:16-27.
213. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
214. Starkov A.A. The role of mitochondria in reactive oxygen species metabolism and signaling. Annals of the New York Academy of Sciences 2008, 1147:37-52.
215. Sterky F.H., Hoffman A.F., Milenkovic D., Bao B., Paganelli A., Edgar D., Wibom R., Lupica C.R., Olson L., Larsson N.G. Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Human Molecular Genetics 2012, 21:1078-1089.
216. Storch A., Jost W.H., Vieregge P., Spiegel J., Greulich W., Durner J., Muller T., Kupsch A., Henningsen H., Oertel W.H., Fuchs G., Kuhn W., Niklowitz P., Koch R., Herting B., Reichmann H. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Archives of Neurology 2007, 64:938-944.
217. Sun Y., Vashisht A.A., Tchieu J., Wohlschlegel J.A., Dreier L. Voltage-dependent anion channels (VDACs) recruit Parkin to defective mitochondria to promote mitochondrial autophagy. The Journal of Biological Chemistry 2012, 287:40652-40660.
218. Surmeier D.J. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurology 2007, 6:933-938.
219. Surmeier D.J., Guzman J.N., Sanchez-Padilla J., Schumacker PT The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease. Neuroscience 2011, 198:221-231.
220. Swerdlow R.H., Parks J.K., Cassarino D.S., Binder D.R., Bennett J.P., Di Iorio G., Golbe L.I., Parker W.D. Biochemical analysis of cybrids expressing mitochondrial DNA from Contursi kindred Parkinson's subjects. Experimental Neurology 2001, 169:479-485.
221. Taira T., Saito Y., Niki T., Iguchi-Ariga S.M., Takahashi K., Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Reports 2004, 5:213-218.
222. Tanaka Y., Engelender S., Igarashi S., Rao R.K., Wanner T., Tanzi R.E., Sawa A.V., Dawson L.D., Ross CA T.M. Inducible expression of mutant alpha-synuclein decreases proteasome activity and increases sensitivity to mitochondria-dependent apoptosis. Human Molecular Genetics 2001, 10:919-926.
223. Tang B., Xiong H., Sun P., Zhang Y., Wang D., Hu Z., Zhu Z., Ma H., Pan Q., Xia J.H., Xia K., Zhang Z Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Human Molecular Genetics 2006, 15:1816-1825.
224. Tanner C.M., Kamel F., Ross G.W., Hoppin J.A., Goldman S.M., Korell M., Marras C., Bhudhikanok G.S., Kasten M., Chade A.R., Comyns K., Richards M.B., Meng C., Priestley B., Fernandez H.H., Cambi F., Umbach D.M., Blair A., Sandler D.P., Langston J.W. Rotenone, paraquat, and Parkinson's disease. Environmental Health Perspectives 2011, 119:866-872.
225. Thiruchelvam M., Richfield E.K., Goodman B.M., Baggs R.B., Cory-Slechta D.A. Developmental exposure to the pesticides paraquat and maneb and the Parkinson's disease phenotype. Neurotoxicology 2002, 23:621-633.
226. Thiruchelvam M., Prokopenko O., Cory-Slechta D.A., Buckley B., Mirochnitchenko O. Overexpression of superoxide dismutase or glutathione peroxidase protects against the paraquat + maneb-induced Parkinson disease phenotype. The Journal of Biological Chemistry 2005, 280:22530-22539.
227. Thomas B., Beal MF Parkinson's disease. Human Molecular Genetics 16 Spec No. 2007, 2:R183-R194.
228. Twig G., Elorza A., Molina A.J., Mohamed H., Wikstrom J.D., Walzer G., Stiles L., Haigh S.E., Katz S., Las G., Alroy J., Wu M., Py B.F., Yuan J., Deeney J.T., Corkey B.E., Shirihai O.S. Fission and selective fusion govern mitochondrial segregation and elimination by autophagy. The EMBO Journal 2008, 27:433-446.
229. Uversky V.N. Neuropathology, biochemistry, and biophysics of alpha-synuclein aggregation. Journal of Neurochemistry 2007, 103:17-37.
230. Valente E.M., Abou-Sleiman P.M., Caputo V., Muqit M.M., Harvey K., Gispert S., Ali Z., Del Turco D., Bentivoglio A.R., Healy D.G., Albanese A., Nussbaum R., Gonzalez-Maldonado R., Deller T., Salvi S., Cortelli P., Gilks W.P., Latchman D.S., Harvey R.J., Dallapiccola B., Auburger G., Wood N.W. Hereditary early-onset Parkinson's disease caused by mutations in PINK1. Science 2004, 304:1158-1160.
231. Van Remmen H., Qi W., Sabia M., Freeman G., Estlack L., Yang H., Mao Guo Z., Huang T.T., Strong R., Lee S., Epstein C.J., Richardson A. Multiple deficiencies in antioxidant enzymes in mice result in a compound increase in sensitivity to oxidative stress. Free Radical Biology & Medicine 2004, 36:1625-1634.
232. Varastet M., Riche D., Maziere M., Hantraye P Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in Parkinson's disease. Neuroscience 1994, 63:47-56.
233. Vercammen L., Van der Perren A., Vaudano E., Gijsbers R., Debyser Z., Van den Haute C., Baekelandt V. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Molecular therapy. The Journal of the American Society of Gene Therapy 2006, 14:716-723.
234. Vives-Bauza C., Andreu A.L., Manfredi G., Beal M.F., Janetzky B., Gruenewald T.H., Lin M.T. Sequence analysis of the entire mitochondrial genome in Parkinson's disease. Biochemical and Biophysical Research Communications 2002, 290:1593-1601.
235. Wang X.F., Li S., Chou A.P., Bronstein JM Inhibitory effects of pesticides on proteasome activity: implication in Parkinson's disease. Neurobiology of Disease 2006, 23:198-205.
236. Wang H.L., Chou A.H., Yeh T.H., Li A.H., Chen Y.L., Kuo Y.L., Tsai S.R., Yu S.T. PINK1 mutants associated with recessive Parkinson's disease are defective in inhibiting mitochondrial release of cytochrome c. Neurobiology of Disease 2007, 28:216-226.
237. Wang H.L., Chou A.H., Wu A.S., Chen S.Y., Weng Y.H., Kao Y.C., Yeh T.H., Chu P.J., Lu C.S. PARK6 PINK1 mutants are defective in maintaining mitochondrial membrane potential and inhibiting ROS formation of substantia nigra dopaminergic neurons. Biochimica et Biophysica Acta 2011, 1812:674-684.
238. Wang Y., Shi M., Chung K.A., Zabetian C.P., Leverenz J.B., Berg D., Srulijes K., Trojanowski J.Q., Lee V.M., Siderowf A.D., Hurtig H., Litvan I., Schiess M.C., Peskind E.R., Masuda M., Hasegawa M., Lin X., Pan C., Galasko D., Goldstein D.S., Jensen P.H., Yang H., Cain K.C., Zhang J. Phosphorylated alpha-synuclein in Parkinson's disease. Science Translational Medicine 2012, 121(4):ra120.
239. Wen Y., Li W., Poteet E.C., Xie L., Tan C., Yan L.J., Ju X., Liu R., Qian H., Marvin M.A., Goldberg M.S., She H., Mao Z., Simpkins J.W., Yang S.H. Alternative mitochondrial electron transfer as a novel strategy for neuroprotection. The Journal of Biological Chemistry 2011, 286:16504-16515.
240. West A.B., Moore D.J., Biskup S., Bugayenko A., Smith W.W., Ross C.A., Dawson V.L., Dawson T.M. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proceedings of the National Academy of Sciences of the United States of America 2005, 102:16842-16847.
241. Wilson C.J., Callaway J.C. Coupled oscillator model of the dopaminergic neuron of the substantia nigra. Journal of Neurophysiology 2000, 83:3084-3100.
242. Winklhofer K.F., Haass C. Mitochondrial dysfunction in Parkinson's disease. Biochimica et Biophysica Acta 2010, 1802:29-44.
243. Winklhofer K.F., Tatzelt J., Haass C. The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases. The EMBO Journal 2008, 27:336-349.
244. Wood-Kaczmar A., Gandhi S., Yao Z., Abramov A.Y., Miljan E.A., Keen G., Stanyer L., Hargreaves I., Klupsch K., Deas E., Downward J., Mansfield L., Jat P., Taylor J., Heales S., Duchen M.R., Latchman D., Tabrizi S.J., Wood N.W. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PloS One 2008, 3:e2455.
245. Wu B.L., Song B., Tian S.Z., Huo S.H., Cui C.X., Guo Y.S., Liu H.J. Central nervous system damage due to acute paraquat poisoning: a neuroimaging study with 3.0T MRI. Neurotoxicology 2012, 33(5):1330-1337.
246. Yang W., Tiffany-Castiglioni E. The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SH-SY5Y cells: relevance to the dopaminergic pathogenesis. Journal of Toxicology and Environmental Health Part A 2005, 68:1939-1961.
247. Yang Y., Gehrke S., Imai Y., Huang Z., Ouyang Y., Wang J.W., Yang L., Beal M.F., Vogel H., Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:10793-10798.
248. Yang W., Chen L., Ding Y., Zhuang X., Kang U.J. Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Human Molecular Genetics 2007, 16:2900-2910.
249. Yang Y., Ouyang Y., Yang L., Beal M.F., McQuibban A., Vogel H., Lu B. Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:7070-7075.
250. Yokota T., Sugawara K., Ito K., Takahashi R., Ariga H., Mizusawa H. Down regulation of DJ-1 enhances cell death by oxidative stress, ER stress, and proteasome inhibition. Biochemical and Biophysical Research Communications 2003, 312:1342-1348.
251. Yoshino H., Nakagawa-Hattori Y., Kondo T., Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. Journal of Neural Transmission Parkinson's Disease and Dementia Section 1992, 4:27-34.
252. Yu W., Sun Y., Guo S., Lu B. The PINK1/Parkin pathway regulates mitochondrial dynamics and function in mammalian hippocampal and dopaminergic neurons. Human Molecular Genetics 2011, 20:3227-3240.
253. Yumino K., Kawakami I., Tamura M., Hayashi T., Nakamura M. Paraquat- and diquat-induced oxygen radical generation and lipid peroxidation in rat brain microsomes. Journal of Biochemistry 2002, 131:565-570.
254. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., de Yebenes J.G. The new mutation E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Annals of Neurology 2004, 55:164-173.
255. Zhang J., Fitsanakis V.A., Gu G., Jing D., Ao M., Amarnath V., Montine T.J. Manganese ethylene-bis-dithiocarbamate and selective dopaminergic neurodegeneration in rat: a link through mitochondrial dysfunction. Journal of Neurochemistry 2003, 84:336-346.
256. Zhang L., Shimoji M., Thomas B., Moore D.J., Yu S.W., Marupudi N.I., Torp R., Torgner I.A., Ottersen O.P., Dawson T.M., Dawson V.L. Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis. Human Molecular Genetics 2005, 14:2063-2073.
257. Zhang L., Zhang C., Zhu Y., Cai Q., Chan P., Ueda K., Yu S., Yang H. Semi-quantitative analysis of alpha-synuclein in subcellular pools of rat brain neurons: an immunogold electron microscopic study using a C-terminal specific monoclonal antibody. Brain Research 2008, 1244:40-52.
258. Zhang X., Zhou J.Y., Chin M.H., Schepmoes A.A., Petyuk V.A., Weitz K.K., Petritis B.O., Monroe M.E., Camp D.G., Wood S.A., Melega W.P., Bigelow D.J., Smith D.J., Qian W.J., Smith R.D. Region-specific protein abundance changes in the brain of MPTP-induced Parkinson's disease mouse model. Journal of Proteome Research 2010, 9:1496-1509.
259. Zhong N., Xu J. Synergistic activation of the human MnSOD promoter by DJ-1 and PGC-1alpha: regulation by SUMOylation and oxidation. Human Molecular Genetics 2008, 17:3357-3367.
260. Zhou Y., Shie F.S., Piccardo P., Montine T.J., Zhang J. Proteasomal inhibition induced by manganese ethylene-bis-dithiocarbamate: relevance to Parkinson's disease. Neuroscience 2004, 128:281-291.
261. Zhu C., Vourc'h P., Fernagut P.O., Fleming S.M., Lacan S., Dicarlo C.D., Seaman R.L., Chesselet M.F. Variable effects of chronic subcutaneous administration of rotenone on striatal histology. The Journal of Comparative Neurology 2004, 478:418-426.
262. Zimprich A., Biskup S., Leitner P., Lichtner P., Farrer M., Lincoln S., Kachergus J., Hulihan M., Uitti R.J., Calne D.B., Stoessl A.J., Pfeiffer R.F., Patenge N., Carbajal I.C., Vieregge P., Asmus F., Muller-Myhsok B., Dickson D.W., Meitinger T., Strom T.M., Wszolek Z.K., Gasser T. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.
263. Zorzano A., Liesa M., Sebastian D., Segales J., Palacin M. Mitochondrial fusion proteins: dual regulators of morphology and metabolism. Seminars in Cell & DevelopmentalB 2010, 21:566-574.